Pharmaceutical manufacturers are potentially facing increased enforcement along with accelerating changes in policy and regulation in the wake of COVID-19, according to partner Kelly Jones Howell.

Writing in the 2021 Sedgwick State of the National Brand Recall Index, Kelly advises that she sees greater scrutiny and potential litigation ahead, despite the industry’s success in helping the world emerge from a devastating pandemic.

The Sedgwick index includes insights from thought leaders addressing risks in various industries, including medical devices, life sciences, food and beverage, automotive and others. Kelly’s article appears on page 31.